Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,486 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07664007 | Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma. | completed | N/A | 18 | Instituto de Investigación Sanitaria AragónOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY |
| 26 |
| Jun 18, 2026 |
| clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | completed | Phase 1 | 39 | AdaptimmuneINDUSTRY | 4 | Jun 17, 2026 | clinicaltrials |
| NCT00554372 | A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 30 | Jennerex BiotherapeuticsINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT03307408 | Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease(CHALNA) | completed | — | 180 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04829383 | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma(AB7) | completed | Phase 2 | 6 | Howard S HochsterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03158818 | Chronic Hepatitis B Virus Infection in Zambia(HUTCH) | completed | — | 326 | University of Alabama at BirminghamOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03311152 | Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis(SEPT9_CROSS) | completed | N/A | 639 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05773105 | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | completed | Phase 1 / Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02562755 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone(PHOCUS) | completed | Phase 3 | 459 | SillaJen, Inc.INDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT04954339 | DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab(DYNAMIC) | completed | Phase 2 | 40 | Tae Won KimOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05667064 | Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study | completed | — | 1,200 | AstraZenecaINDUSTRY | 0 | Jun 1, 2026 | clinicaltrials |
| NCT04687969 | Multimodal Machine Learning Characterization of Solid Tumors | completed | — | 50 | Ciprian Catana, MD, PhDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05099848 | A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma | completed | Phase 2 | 21 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07598331 | Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCC(SBS-CEUS) | completed | N/A | 106 | The First Hospital of Jilin UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06626087 | A Prototype AI Algorithm Versus Liver Imaging Reporting and Data System (LI-RADS) Criteria in Diagnosing HCC on CT(Hepatocellular) | completed | N/A | 300 | The University of Hong KongOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02305459 | CIRSE Registry for SIR-Spheres Therapy(CIRT) | completed | — | 1,051 | Cardiovascular and Interventional Radiological Society of EuropeOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03033446 | Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma | completed | Phase 2 | 40 | National Cancer Centre, SingaporeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06881446 | Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions | completed | — | 2,651 | Zhongda HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04358185 | Itacitinib in Advanced Hepatocellular Carcinoma(JAKaL) | completed | Phase 1 | 19 | Imperial College LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06261047 | Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer | completed | — | 36 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT02366286 | Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants | completed | — | 892 | Mayo ClinicOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05625893 | Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion | completed | Phase 2 | 63 | Samsung Medical CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT01899261 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | N/A | 20 | Montefiore Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05332496 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC(CHANCE2202) | completed | — | 941 | Zhongda HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05332821 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC(CHANCE2201) | completed | — | 1,244 | Zhongda HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06233981 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis | completed | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02771405 | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC(FRI-STC) | completed | Phase 3 | 150 | National Hepatology & Tropical Medicine Research InstituteOTHER_GOV | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06086002 | Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular Carcinoma | completed | N/A | 20 | Seoul National University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07192172 | Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes(ERFA) | completed | N/A | 100 | Seoul National University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04834674 | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT00116454 | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis(Lipiocis) | completed | Phase 3 | 73 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT05807776 | Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. | completed | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02435953 | TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma(TORCH) | completed | Phase 3 | 241 | Ming ZhaoOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04620538 | Volatile Organic Compounds for the Assessment of Liver Disease(VOCAL) | completed | — | 56 | Imperial College LondonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06311396 | Development of a Neuronal Microscope | completed | N/A | 30 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04903548 | Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres | completed | — | 1 | Methodist Health SystemOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03753659 | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 30 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | completed | Phase 3 | 344 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06354387 | Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | completed | Phase 1 | 5 | China Medical University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483242 | Individualized Surgical Guidance in HCC-BDTT | completed | — | 151 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 23, 2026source: clinicaltrials